3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Breast
1
Conditions
Breast Neoplasms
211
Neoplasm Metastasis
16
Neoplasms
9
Breast Neoplasms, Male
7
Breast Diseases
7
Ovarian Neoplasms
4
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Intraductal, Noninfiltrating
3
Breast Carcinoma In Situ
3
Breast Cancer Metastatic
3
Advanced Breast Cancer
3
Recurrence
2
Prostatic Neoplasms
2
Neoplasms by Site
2
Carcinoma, Renal Cell
2
Bulbo-Spinal Atrophy, X-Linked
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Tuberous Sclerosis
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sleep Wake Disorders
1
Skin Diseases
1
Sexuality
1
Sexual Dysfunctions, Psychological
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Primary Breast Cancer ER+ve
1
Interventions
Carboplatin
9
Pemetrexed
7
osimertinib
5
pembrolizumab
3
entinostat
3
durvalumab
3
Radiosurgery
3
Cisplatin
3
Bevacizumab
3
selpercatinib
2
camrelizumab
2
Paclitaxel
2
Gemcitabine
2
Erlotinib Hydrochloride
2
Docetaxel
2
trametinib
1
sotorasib
1
repotrectinib
1
pralsetinib
1
patritumab
1
nazartinib
1
napabucasin
1
icotinib
1
exemestane
1
cobimetinib
1
ceralasertib
1
cemiplimab
1
capmatinib
1
atezolizumab
1
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Bronchial Neoplasms
×
exemestane
×
Clear all
NCT01594398
2021-11-19
ENCORE110
Syndax Pharmaceuticals
Phase 1
Completed
14 enrolled